Abstract
The availability of high-throughput genotyping and sequencing platforms has largely removed technological barriers in the mapping the genetic determinants of drug response in human populations, and the set of validated pharmacogenetic variants is gradually increasing. Like the search for disease-susceptibility variation, however, many of the loci identified to date represent the relatively low-hanging fruit with large phenotypic effects but relatively low predictive power. Yet to be discovered is the larger set of variants, each with considerably weaker phenotypic effects, which together can be used to predict drug response more reliably and identify potential targets for novel drug development. Finding these pharmacogenetic variants is particularly challenging because sample size is typically far too small (and thus statistically underpowered) to detect genetic variants with weak effects. Studies of the genetics of gene expression (also described as expression quantitative locus (eQTL) mapping or genetical genomics) represent a novel approach for identification of functional genetic variants that influence gene expression. In these studies, individual gene transcript abundance as measured from expression microarrays are considered as discrete quantitative traits for genetic mapping that are intermediate to clinical outcomes of interest. Early studies using these methods have demonstrated improved power to detect such regulatory variants and have facilitated mapping of disease-susceptibility variants. The potential use of this approach in the study of pharmacogenetics and for the identification of potentially modifiable drug targets is reviewed here.
Keywords: Pharmacogenetics, gene expression, genetical genomics, complex trait
Current Pharmaceutical Design
Title: Genetic Mapping of Pharmacogenetic Regulatory Variation
Volume: 15 Issue: 32
Author(s): Benjamin A. Raby
Affiliation:
Keywords: Pharmacogenetics, gene expression, genetical genomics, complex trait
Abstract: The availability of high-throughput genotyping and sequencing platforms has largely removed technological barriers in the mapping the genetic determinants of drug response in human populations, and the set of validated pharmacogenetic variants is gradually increasing. Like the search for disease-susceptibility variation, however, many of the loci identified to date represent the relatively low-hanging fruit with large phenotypic effects but relatively low predictive power. Yet to be discovered is the larger set of variants, each with considerably weaker phenotypic effects, which together can be used to predict drug response more reliably and identify potential targets for novel drug development. Finding these pharmacogenetic variants is particularly challenging because sample size is typically far too small (and thus statistically underpowered) to detect genetic variants with weak effects. Studies of the genetics of gene expression (also described as expression quantitative locus (eQTL) mapping or genetical genomics) represent a novel approach for identification of functional genetic variants that influence gene expression. In these studies, individual gene transcript abundance as measured from expression microarrays are considered as discrete quantitative traits for genetic mapping that are intermediate to clinical outcomes of interest. Early studies using these methods have demonstrated improved power to detect such regulatory variants and have facilitated mapping of disease-susceptibility variants. The potential use of this approach in the study of pharmacogenetics and for the identification of potentially modifiable drug targets is reviewed here.
Export Options
About this article
Cite this article as:
Raby A. Benjamin, Genetic Mapping of Pharmacogenetic Regulatory Variation, Current Pharmaceutical Design 2009; 15 (32) . https://dx.doi.org/10.2174/138161209789649466
DOI https://dx.doi.org/10.2174/138161209789649466 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNAs: A Critical Regulator and a Promising Therapeutic and Diagnostic Molecule for Diabetic Cardiomyopathy
Current Gene Therapy Medical Treatment of Aortic Aneurysms in Marfan Syndrome and other Heritable Conditions
Current Cardiology Reviews Folate and Homocysteine Metabolism: Therapeutic Targets in Cardiovascular and Neurodegenerative Disorders
Current Medicinal Chemistry Risk Stratification for Sudden Cardiac Death: Current Approaches and Predictive Value
Current Cardiology Reviews The Immunoproteasome as a Therapeutic Target for Hematological Malignancies
Current Cancer Drug Targets Biomarkers Associated with Stroke Risk in Atrial Fibrillation
Current Medicinal Chemistry Sodium-Proton Exchanger Isoform-1: Synthesis of a Potent Inhibitor Labeled with Deuterium and Carbon-14
Current Radiopharmaceuticals Saturation of the Human Phenome
Current Genomics New Biotechnological Methods to Reduce Oxidative Stress in the Cardiovascular System: Focusing on the Bach1/Heme Oxygenase-1 Pathway
Current Pharmaceutical Biotechnology HIV-Infected Patients and Liver Transplantation: Who, When and Why
Current HIV Research Stroke and Neuroinflamation: Role of Sexual Hormones
Current Pharmaceutical Design State of the Art of Nanobiotechnology Applications in Neglected Diseases
Current Nanoscience Damnacanthal-Induced Anti-Inflammation is Associated with Inhibition of NF-κB Activity
Inflammation & Allergy - Drug Targets (Discontinued) Miracles of Herbal Phytomedicines in Treatment of Skin Disorders: Natural Healthcare Perspective
Infectious Disorders - Drug Targets Nonbacterial Thrombotic Endocarditis (Marantic Endocarditis) in Cancer Patients
Cardiovascular & Hematological Disorders-Drug Targets Irbesartan and Hydrochlorothiazide Association in the Treatment of Hypertension
Current Vascular Pharmacology Use of Mouse Models to Evaluate Roles of Nuclear Receptors and their Ligands in the Pathogenesis and Treatment of Atherosclerosis
Current Drug Targets Preface: MicroRNA as Disease Biomarkers
MicroRNA Memory Impairment is Associated with Serum Methylarginines in Older Adults
Current Alzheimer Research Virulence Potential of Staphylococcus aureus Strains Isolated from Diabetic Foot Ulcers Among Patients from Southern Poland
Current Vascular Pharmacology